Pharmacy in the US …

The worse?

Or the best?
Prof. Schentag is here to tell us that it is probably the best ...

When did start the story of pharmacist involvement in antibiotic management?
Prof. Schentag is a pioneer pharmacist in antibiotic use optimization!
From PK to prevention of toxicity…

Schentag et al.  
Gentamicin tissue accumulation and nephrotoxic reactions.  

Mangione & Schentag.  
Therapeutic monitoring of aminoglycoside antibiotics: an approach.  

Kazierad et al.  
The effect of verapamil on the nephrotoxic potential of gentamicin as measured by urinary enzyme excretion in healthy volunteers.  


JJ. Schentag is the father of the AUC/MIC concept!

Forrest et al.
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Schentag.
Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.

Moise et al.
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus.
Am J Health Syst Pharm. 2000 57 Suppl 2:S4-9
Pharmacists and pharmacoeconomics


Paladino et al. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US. Pharmacoeconomics. 2007 25:677-83
Pharmacists and antibiotic policies

Schentag.  
**Antimicrobial management strategies** for Gram-positive bacterial resistance in the intensive care unit.  

Schentag et al.  
What have we learned from **pharmacokinetic and pharmacodynamic** theories?  

Schentag.  
**Understanding and managing microbial resistance** in institutional settings.  
Am J Health Syst Pharm. 1995 52(6 Suppl 2):S9-14
Clinical pharmacy development

Schentag et al.
Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory.

Schentag.
The results of a targeted pharmacy intervention program.

Gresala et al.
A clinical pharmacy-oriented drug surveillance network: II. Results of a pilot project.
Which type of pharmacist would like to become tomorrow?

This one?

Or this one?

Or this one?